Elastin-like polypeptide nanoparticles for targeted siRNA delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering siRNA therapeutics face challenges such as rapid degradation in the body and non-specific accumulation in organs like the liver and kidney, leading to off-target effects and reduced efficacy, due to the lack of efficient targeting mechanisms for cancer cells.
Innovation Solution
Development of elastin-like polypeptide (ELP) nanoparticles that can complex with siRNA and include specific cell-targeting domains, allowing for targeted delivery to cancer cells by forming stable complexes and localizing specifically to tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-targeted nanoparticles are used to deliver siRNA, then tumor accumulation and target gene silencing occur, but significant accumulation in liver, kidney and spleen leads to off-target effects and reduced effective doses
Solution Approach 1:
The nanoparticle surface is engineered with specific targeting moieties (such as antibodies, peptide ligands, or aptamers) that recognize and bind to markers uniquely expressed on tumor cell surfaces. This creates local specificity at the tumor site, allowing the nanoparticle to accumulate selectively in tumors while minimizing accumulation in normal organs like liver, kidney and spleen, thereby reducing off-target effects
Solution Approach 2:
Targeting moieties serve as intermediary elements between the nanoparticle and tumor cells. These moieties (antibodies, peptide ligands, aptamers) mediate the interaction by specifically binding to tumor markers, facilitating targeted delivery while preventing non-specific accumulation in healthy tissues
2Reliability
If siRNA is administered systemically, then tumor accumulation occurs, but rapid degradation by RNA nucleases reduces therapeutic effectiveness
Solution Approach 1:
The nanoparticle acts as a protective intermediary carrier that shields siRNA from nucleases in the circulation. The nanoparticle core provides a protected environment where siRNA remains stable and intact, preventing degradation while maintaining delivery capability to tumor cells
Solution Approach 2:
The nanoparticle surface forms a protective shell around the siRNA payload. This shell structure physically barriers nucleases from degrading the siRNA, providing stability in the circulatory system while allowing the nanoparticle to reach and deliver the intact siRNA to tumor cells
3Productivity
If conventional small molecule drugs are synthesized and screened, then therapeutic agents can be developed, but the process takes a long time compared to siRNA design
Solution Approach 1:
The therapeutic approach is segmented into two independent components: (1) selection of a target mRNA sequence based on cancer genetics, and (2) design of complementary siRNA sequences. This segmentation allows parallel optimization of target selection and siRNA design, significantly accelerating development compared to the sequential synthesis and screening required for small molecule drugs
Solution Approach 2:
The approach changes the fundamental parameter of drug design from chemical structure optimization (small molecules) to nucleic acid sequence complementarity (siRNA). By designing siRNA based on mRNA sequence information, the process leverages existing genomic data to rapidly identify effective sequences without time-consuming chemical synthesis and activity screening
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ELP nanoparticles effectively protect siRNA from degradation, facilitate targeted delivery to cancer cells, and demonstrate specific localization and metabolism by tumors, enhancing therapeutic efficacy while minimizing off-target effects.
Implementation Method 1
Polypeptide delivery vehicles of the invention generally comprise an elastin-like polypeptide (ELP) in complex with a therapeutic molecule... an ELP composition may comprise an ELP complexed with a therapeutic small molecule, polypeptide or nucleic acid
Implementation Method 2
include specific cell-targeting domains, allowing for targeted delivery to cancer cells by forming stable complexes and localizing specifically to tumors... demonstrate specific localization and metabolism by tumors
Data Source
AI summary
This invention describes a protein nanoparticle system for targeting siRNA or other drugs into tumors. The basis of the protein system is elastin-like peptides that self-assemble once exposed to the nucleic acid of the siRNA. Specific targeting peptides are fused to the core ELP structure by standard genetic engineering techniques. These targeting peptides confer specific binding of the nanoparticle to receptors on the surface of tumor cells and allow for uptake of the nanoparticle into the tumor cells.